Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 35,344 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
Interventions: Durvalumab, Tremelimumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Suicide
Interventions: Safety Planning Intervention with Navigation Services; Behavioral
Lead sponsor: San Diego State University; Other
Eligibility: 15 Years to 29 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV
Interventions: IFx-Hu2.0; Biological
Lead sponsor: TuHURA Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Invasive Candidiasis
Interventions: therapy duration; Other
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 120 Days and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 21
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 17 more

Conditions: Advanced Solid Tumors
Interventions: G-202; Drug
Lead sponsor: GenSpera, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 3
States / cities: Baltimore, Maryland • San Antonio, Texas • Madison, Wisconsin

Conditions: Autologous Fat Grafting
Interventions: 2-Dimensional (2-D) Photographs (Visit 1/ Follow up Visit 3-6), 3-Dimensional (3-D) Photographs (Visit 1- 6), Ultrasound Soft Tissue Assessment (Visit 1/ Follow up Visit 4-6), Magnetic Resonance Imaging Volume Assessment (Visit 1/ Follow up Visit 4-6), BREAST-QTM questionnaire (Visit 1/ Follow up Visit 4-6); Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Houston, Texas

Conditions: Venous Stenosis, Venous Occlusion
Interventions: Merit WRAPSODY Endovascular Stent Graft, PTA; Device
Lead sponsor: Merit Medical Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 33
States / cities: Tempe, Arizona • Tucson, Arizona • Orange, California + 26 more

Conditions: Advanced Solid Tumors
Interventions: MEDI5083 monotherapy, MEID5083 with Durvalumab or Tremelimumab, Medi5083 with Durvalumab and Docetaxel; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 101 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Hackensack, New Jersey • Providence, Rhode Island • Nashville, Tennessee + 1 more

Conditions: Glioblastoma
Interventions: B-cell vaccination; Biological
Lead sponsor: Catalina Lee Chang; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions: Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2035
U.S. locations: 1160
States / cities: Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more

Conditions: Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
Interventions: PF-07934040, Gemcitabine, Nab-paclitaxel, Cetuximab, Fluorouracil, Oxaliplatin, Leucovorin, Bevacizumab, Pembrolizumab, pemetrexed, Cisplatin, Paclitaxel, Carboplatin, Sasanlimab; Drug · Combination Product
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 14 more

Conditions: Heart Failure, Cardiomyopathies
Interventions: EXCOR Pediatric; Device
Lead sponsor: Berlin Heart, Inc; Industry
Eligibility: 1 Day to 16 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 15
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 12 more

Conditions: Crohn Disease (CD), Ulcerative Colitis (UC), Indeterminate Colitis
Interventions: Vaccine Education; Other
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelofibrosis
Interventions: Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg; Drug
Lead sponsor: Geron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Duarte, California • La Jolla, California + 26 more

Conditions: Generalized Myasthenia Gravis
Interventions: YTB323; Genetic
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Orange, California • Winston-Salem, North Carolina • Philadelphia, Pennsylvania + 1 more

Conditions: Caffeine, Sleep Deprivation, Shift-Work Related Sleep Disturbance
Interventions: Caffeine; Dietary Supplement
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 39 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Scleroderma
Interventions: MEDI-546; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 11
States / cities: Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 7 more

Conditions: Hyperkalemia
Interventions: RDX013, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 6
States / cities: Coral Gables, Florida • Miami Lakes, Florida • Miami Springs, Florida + 3 more

Conditions: Pyoderma Gangrenosum
Interventions: Platelet rich plasma therapy; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Intubation; Difficult or Failed
Interventions: Intervention: Receives Training, Intervention: Control No Training; Procedure · Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 89 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Feeding Tube Complication
Interventions: Placement of stoma site enteral feeding tube accessory; Device
Lead sponsor: Eric Yudelevich; Other
Eligibility: 22 Years to 85 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Colorectal Cancer, Advanced Adenocarcinoma, Serrated Polyp
Interventions: ColoSense; Diagnostic Test
Lead sponsor: Geneoscopy, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 14,263 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: St Louis, Missouri • Austin, Texas

Conditions: Healthy
Interventions: PT2385; Drug
Lead sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Well-Being, Psychological
Interventions: Conversational Agent Zenny, Web-based Wellness Resources; Behavioral
Lead sponsor: University of Klagenfurt; Other
Eligibility: 18 Years and older
Enrollment: 1,595 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Menlo Park, California

Search by objective public record fields.

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Suicide Prevention for Sexual and Gender Minority Youth (Open Trial)

pDNA Intralesional Cancer Vaccine for Cutaneous Melanoma

Comparison of Uncomplicated Candidemia Therapy Duration in Children and Adults

Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors

Quantitative Assessment of Autologous Fat Transfer

The Merit WRAPSODY AV Access Efficacy Study (WAVE)

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device

Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis

Real-Time Caffeine Optimization During Total Sleep Deprivation

A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma

A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia

Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum

Manikin To Patient Intubation: Does It Translate?

Safety and Efficacy of Enteral Feeding Tube Stoma Site Accessory

Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study

PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers

A Bot-based Self-help Program (WELL)